APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Clinical trial NCT04638309 · TERMINATED
Trial details
- NCT number
- NCT04638309
- Sponsor
- Aprea Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-20
- Primary completion
- 2022-04-25
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.